基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
动态炎症生物标志物作为接受 PD-1 抑制剂治疗的晚期乳腺癌患者的预后指标
英文原题：Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors.
查看英文原题
Dynamic inflammatory biomarkers as prognostic indicators in advanced breast cancer patients receiving PD-1 inhibitors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
CRP 和 NLR 是预测 ABC 患者 PD-1 抑制剂治疗结局的有前景的生物标志物，在个体化免疫治疗策略方面具有潜在应用价值。
中文摘要
背景
程序性死亡蛋白 1（PD-1）抑制剂可使乳腺癌患者获益，但缺乏简便的疗效预测指标。
目的
评估炎症标志物能否作为接受免疫治疗的晚期乳腺癌（ABC）患者预后指标。 设计：单中心回顾性研究，纳入 2016 年 1 月至 2022 年 6 月接受 PD-1 抑制剂治疗的 ABC 患者。
方法
收集 116 名患者基线及免疫治疗 3 个周期后的临床病理参数、TIL（肿瘤浸润淋巴细胞）水平和炎症标志物，包括 C 反应蛋白（CRP）、中性粒细胞/淋巴细胞比值（NLR）和淋巴细胞/单核细胞比值（LMR）；治疗 3 周期后的指标记为 CRP3、NLR3、LMR3。使用 R 软件确定最佳截点，并评估其与无进展生存期（PFS）、总生存期（OS）及客观缓解率的关系。
结果
Kaplan-Meier 分析显示，基线 CRP 低、NLR 低和 LMR 高均与 PFS、OS 改善显著相关（均 p<0.05）。多变量分析中，NLR3 较低和 CRP3/CRP 比值下降可独立预测 PFS 延长（p<0.05）。CRP 低、CRP3/CRP 比值下降、NLR 低和 NLR3 低的患者 OS 更好（p<0.05）。炎症标志物与 TIL 状态结合改善了预后分层：TIL 缺乏且 NLR3 高的患者（PFS 中位数 2.89 个月）或 CRP3/CRP 比值高的患者（PFS 中位数 1.90 个月）生存最差（p<0.05）。
结论
CRP 和 NLR 是预测 PD-1 抑制剂治疗 ABC 结局的有希望生物标志物，可能有助于个体化免疫治疗策略。
展开英文摘要原文
BACKGROUND
While programmed cell death protein 1 (PD-1) inhibitors benefit breast cancer patients, simple predictors of their efficacy are lacking.
OBJECTIVES
This study aimed to evaluate inflammatory markers as prognostic indicators for advanced breast cancer (ABC) patients receiving immunotherapy. DESIGN: This is a single-center retrospective study of ABC patients treated with PD-1 inhibitors between January 2016 and June 2022.
METHODS
Clinicopathological parameters, tumor-infiltrating lymphocytes (TILs) levels, and inflammatory markers-C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR)-were collected from 116 ABC patients at baseline and after three cycles of immunotherapy (CRP3, NLR3, LMR3). Optimal cut-offs were defined using R software and associations with progression-free survival (PFS), overall survival (OS), and objective response rate were assessed.
RESULTS
Low baseline CRP, low NLR, and high LMR were significantly associated with improved PFS and OS (all p < 0.05) by Kaplan-Meier analysis. On multivariate analysis, low NLR3 and a reduced CRP3/CRP ratio independently predicted prolonged PFS ( p < 0.05). Patients with low CRP, reduced CRP3/CRP ratio, low NLR, and low NLR3 achieved better OS ( p < 0.05). Combining inflammatory markers with TIL status improved prognostic classification: TIL-deficient patients with high NLR3 (median PFS (mPFS): 2.89 months) or high CRP3/CRP ratio (mPFS: 1.90 months) had the poorest survival ( p < 0.05).
CONCLUSION
CRP and NLR are promising biomarkers for predicting outcomes of PD-1 inhibitor therapy in ABC, with potential utility in individualizing immunotherapy strategies.
论文信息
- 作者
- Wang N、Yi P、Lu Q、Zhong Y、Xue C、Zhang P、Wang S、Yuan Z
- 第一作者单位
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.China
- 通讯作者单位
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, Guangdong 510060, P.R. China.China
- 期刊
- Therapeutic advances in medical oncology2026
- 原文标识
- PubMed 42153091 · DOI 10.1177/17588359261443939
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →